X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Abbvie

AbbVie Inc. has settled its Delaware patent infringement suit against Boehringer Ingelheim, granting the German drugmaker a nonexclusive license to begin selling a biosimilar of its $20 billion immunosuppressant Humira in 2023.

Tom McParland

Tom McParland of New York Law Journal can be contacted at tmcparland@alm.com. Follow him on Twitter @TMcParlandALM.

More from this author

Environmental Enforcement: Civil and CriminalBook

The Environmental Enforcement: Civil and Criminal law book explains the
potential legal consequences of enforcement actions and discusses procedures to
follow to minimize exposure.
Get More Information

 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.